Several SMN2 variants have been identified that are associated with milder phenotypes [34–37], but less is known about SMN2 variants that lead to more severe SMA phenotypes or whether certain SMN2 variants are associated with a weaker response to mRNA treatment. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.